Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444
The Centers for Medicare and Medicaid Services (CMS) on July 14 published its proposed Physician Fee Schedule (PFS) for 2027. Similar to the 2026 schedule, one of two conversion factors will be use...
IPG Photonics to Acquire Lumibird Medical for €300 Million
IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...
Kalshi Offers Betting on Drug Development Timelines and Results
Prediction market Kalshi began on July 16 offering betting on a range of drug development milestones, ranging from clinical trial outcomes and timelines for submissions to US FDA decisions. The New...
WOC 2026 Explores How AI Can Expand Access to Eye Care
Artificial intelligence is quickly evolving from a diagnostic tool into a comprehensive clinical assistant with the potential to expand access to eye care worldwide, as emphasized at the 2026 World...
Atsena Will Advance ATSN-401 Gene Therapy Candidate for Stargardt
Atsena Therapeutics announced July 9 that it would advance ATSN-401, a gene therapy candidate for Stargardt disease. Stargardt is an inherited neurodegenerative disease that leads to macular degene...
Ocugen Secures Deal with Roots Pharmaceutical for OCU400 in MENA Region
Ocugen announced July 13 that it had signed a binding term sheet for a license agreement with Kuwait’s Roots Pharmaceutical for exclusive rights to OCU400, Ocugen’s subretinal modifier gene therapy...
Santen Gains Philippines Marketing Approval for Ryjusea (Atropine) for Myopia
Japan’s Santen Pharmaceutical announced June 26 that it had gained marketing approval in the Philippines for preservative-free Ryjusea low-dose atropine drops to slow the progression of pediatric m...
US FDA Grants RMAT Status to Emmecell’s Corneal Cell Therapy Candidate
Emmecell announced July 7 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to EO2002, the company’s corneal endothelial cell therapy candidate. The RMAT designa...
NovaBridge Biosciences Appoints Srishti Gupta, MD, as Chief Executive Officer
NovaBridge Biosciences announced June 29 that it had appointed Srishti Gupta, MD, as chief executive officer and a member of the company’s board of directors. The company said that Xi-Yong (Sean) F...
Exonate Appoints Olav Hellebø as Chief Executive Officer
British company Exonate announced June 30 that it had appointed Olav Hellebø as chief executive officer. Exonate is developing EXN407, an eye drop candidate entering Phase IIb study for diabetic ey...
China’s Myopia Prevention Success Could Reshape a Still-Expanding Market
Recent data presented at the 2026 World Ophthalmology Congress demonstrate that China’s myopia reduction efforts are working. Myopia reduction initiatives by Chinese government agencies call for co...
Octane Analyzes How AI and Practice Workflow are Driving Tech Innovation
The 2026 Octane Ophthalmology Tech Forum focused on how advances in artificial intelligence and physician workflow are influencing the develop-ment and commercialization of new ophthalmic technolog...
Past News Stories
Robotic Cataract Surgery Can Serve as Catalyst for Premium Growth
Robotic cataract surgery remains a hot topic in ophthalmology, fueled by recent first-in-human procedures and a growing pipeline of robotic platforms. A digitally guided, highly precise surgical sy...
RxSight to Collaborate with Alcon on PC-IOLs Under New CEO
RxSight has made two significant moves following disappointing sales results in Q2-2026. The Aliso Viejo, California, company announced July 6 that it would collaborate with Alcon to develop adjust...
LensCrafters Adds Refractive and Cataract Surgery Options to New Center
LensCrafters, part of French company EssilorLuxottica, announced June 30 that it was launching the first LensCrafters Vision & Eye Health Center, adding surgical procedures and advanced diagnostics...
Select US FDA Approvals and Clearances in June 2026
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in June 2026, according to the agency’s database. Topcon received clearance for the Harmony Refer...
PDUFA Dates for Ophthalmic Drug Candidates, July 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
US FDA Approves First Challenger to Tepezza: Lumvoa from Viridian
Viridian Therapeutics announced June 29 that the US FDA had approved Lumvoa (veligrotug-vvze), an infusion treatment for thyroid eye disease (TED). The company said Lumvoa would launch immediately....
MACs Propose Limiting Coverage for iDose TR in Glaucoma Patients
Five Medicare administrative contractors (MACs) in the US are proposing to limit coverage for procedures implanting the Glaukos iDose TR in patients with glaucoma. The iDose TR is a drug-eluting in...
US FDA Advisory Panel Will Review Sydnexis’ NDA for SYD-101 in Myopia
Sydnexis announced July 13 that the US FDA would convene an advisory committee meeting to discuss SYD-101, the company’s low-dose atropine candidate for pediatric progressive myopia. The date for t...
Gene Therapy Research Targets Root Cause of Open-Angle Glaucoma
New research presented at the 2026 World Ophthalmology Congress suggests that gene therapy may offer a way to treat the underlying cause of primary open-angle glaucoma rather than lowering intraocu...
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
Lenz Launches Telehealth Prescribing Option for Vizz Presbyopia Drops
Lenz Therapeutics announced July 6 that it was making its presbyopia drop, Vizz, available online through a telehealth platform at getvizz.com. Lenz said an independent network of licensed eye care...
Ollin Leads Latest Fundraising with $330 Million in Series B Financing
Ollin Biosciences led recent ophthalmic fundraising efforts with $330 million in a Series B round to advance its candidates for retinal and thyroid eye disease. Financing announced in the past four...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.